Zeripatamig

泽帕妥米单抗

Report date: 2024/06/12 17:50:29

First In Class

Base Information

Drug NameZeripatamig

Drug Alias NameTG-1801NI-1701

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitorsB-lymphocyte antigen CD19 inhibitors

TargetsB-lymphocyte antigen CD19Cluster of differentiation 47

Therapy Area/IndicationsRichter's SyndromeLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNovimmune Sa

China Registration ClassN/A

Develop Information

Active CompaniesTg Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsRichter's SyndromeLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7]

Other Information

ATC CodeN/A